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Introduction
Urokinase-type plasmingen activator (uPA) and its receptor are important components of cell surface proteolysis used by tumor cells and capillary endothelial cells for basement membrane invasion and implicated in the progression, metastasis, and angiogenesis of numerous tumors (de Vries et al,, 1996; Andreasen et al., 1997; Reuning et al., 1998) . uPA is secreted from cells as a single-chain proenzyme that is cleaved by plasmin into its two-chain active form (Petersen et al., 1988) . Both the single and two-chain forms can bind to u-PA receptor (uPAR). The two chain form consists of A (aa 158) and B (aa 159-411) polypeptide chains linked by disulfide bonds. Single-chain uPA (scu-PA) is a multidomain protein composed of a carboxyl-terminal protease domain, termed low molecular weight scu-PA (LMW -scu-PA) and an amino-terminal fragment (u-ATF), which can be further subdivided into a growth factor-like domain (aa 4-43) and a kringle domain (aa 45-135) ( Figure  1A ). The general feature of kringle structure is composed of 78-80 amino acids inter-connected by a triple disulfide-linked loop.
The high level expression of uPA and uPA receptor (uPAR) are correlated with a poor prognosis in a num-
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ber of malignancies, including breast, gastric, brain and lung cancer (Sappino et al., 1987; Yamamoto et al., 1994b; Foekens et al., 1995; Park et al., 1997) and is often localized to the leading, invasive edge of a tumor (Estreicher et al., 1990; Yamamoto et al., 1994a) . Blockage of the interaction of uPA and its receptor has resulted in inhibition of the migration and spreading of malignant tumor cells (Crowley et al., 1993; Mohanam et al., 2002) .
During angiogenesis, endothelial cells need to divide, migrate, invade into the extracellular matrix, and form capillary structures from preexisting blood vessels. The process of cell invasion requires the production of a key active cell surface protease, uPA. Treatment of capillary endothelial cells with angiogenic factors such as basic fibroblast growth factor (bFGF) and VEGF causes up-regulation of uPA (Saksela et al., 1987) and uPAR (Mignatti et al., 1991; Mandriota et al., 1995) . Interference with the activities of the uPA system has been demonstrated in some cases inhibition of angiogenesis in vitro (Yasunaga et al., 1989; Lu et al., 1996; Min et al., 1996; Fibbi et al., 1998) , and in vivo (Min et al., 1996; Li et al., 1998) .
ATF-based uPAR antagonists are known to have anti-angiogenic function mainly by blocking uPA/uPAR interaction (Lu et al., 1996; Li et al., 1998) . Recently, the recombinant kringle domain of urokinase (UK1) has been shown to present anti-angiogenic activity in vitro and in vivo by unknown mechanism (Kim et al., 2003b) . Since u-ATF contains potential two inhibitory domains; a growth factor-like domain where uPAR binding domain is located and a kringle domain, it will be an intriguing question whether u-ATF acts like UK1 on endothelial cells or whether u-ATF elicits more potent anti-angiogenic activity than UK1 due to one additional functional epitope. Therefore, in this study, we compared the anti-angiogenic activities of these two molecules.
M aterials and M ethods M aterials
Recombinant scu-PA expressed in Chinese hamster ovary cells was obtained from Mogam Biotechnology Research Institute (Kyungki-do, Korea). The reagents used for cell culture, M199, DMEM, FBS and trypsin solution were purchased from Life Technologies (Gaithersbug, MD). VEGF and bFGF were purchased from R&D system (Minneapolis, MN).
C ell culture
Human umbilical vein endothelial (HUVE) cell was isolated from fresh cords by an adaptation of the method described by Jaffe et al. (1973) , and maintained in M199 medium containing 20% FBS, 30 µg/ml endothelial cell growth supplements (Sigma), 90 µg/ml heparin, 25 mM Hepes, 2.2 g/L sodium bicarbonate, 2 mM L-glutamine and penicillin/ streptomycin antibiotics. Cells at passage 3, 4 or 5 were used for the experiments. Bovine capillary endothelial (BCE) cell was obtained from Dr. TH Lee (Lee et al., 1998) , and maintained in DMEM containing 10% FBS and 1% penicillin/streptomycin antibiotic, and 3 ng/ml bFGF. Cultures were kept at 37 o C in a humidified atmosphere of 10% CO2 in air for BCE cells and 5% CO2 in air for HUVE cells.
Expression and purification of u-ATF
A transformant expressing u-ATF was obtained by transformation of E. coli BL21 (DE3) with pET-21d/ATF which was constructed previously (Kim et al., 2003b) . Expression and purification of u-ATF were performed as previously described for UK1 production. A single colony of the transformant was grown in 2.5 liter of LB medium containing 100 mg/ml of ampicillin at 37 o C to a A600 of about 0.6-0.8. To induce the production of recombinant protein, isopropyl thio-β-D-galactopyranoside (IPTG) was added to a final concentration of 1.0 mM. Cells were incubated for an additional 3 h at 37 o C and finally harvested by centrifugation for 15 min (8,000 g). The cell paste was stored at -70 o C. The cell pellet was thawed, suspended in a lysis buffer [20 mM Tris-Cl, pH 8.0, 50 mM NaCl, 1 mM MgCl2, 0.1 mM CaCl2, RNase A (20 mg/ml), DNase I 50 µg/ml], and subjected to sonication for 15 min. The soluble and insoluble fractions were separated by centrifugation for 30 min at 20,000 g. The insoluble fraction was dissolved in a buffer C (20 mM Tris-Cl, pH 7.9, 0.5 M NaCl, 8 M Urea) and diluted to 6 M urea. After centrifugation, the supernatant was applied to a ProBond TM resin His-tag affinity column equilibrated with buffer D (20 mM Tris-Cl, pH 7.9, 0.5 M NaCl, 6 M urea). The column was washed with 20 µM imidazole-containing buffer D, and protein was eluted with 1 M imidazole-containing buffer D. After confirming by SDS-PAGE, the fractions containing the desired protein were combined and stepwise diluted with buffer F (0.1 M Tris-Cl, 0.15 M NaCl, pH 8.0). While diluted, the solution was added with reduced (1 mM) and oxidized (0.1 mM) glutathione and incubated at room tem perature overnight. The solution was concentrated by ultrafiltration and dialyzed against sodium acetate buffer (pH 5.5) and distilled water. The dialyzed solution was lyophilized, dissolved in buffer G (20 mM sodium phosphate, 150 mM NaCl, pH 6.8), and applied to a Bio-prep SE 100/17 column equilibrated with the same buffer for the final purification. The endotoxin level of the purified proteins was less than 0.3 U/mg protein.
Binding assay by Biacore biosensor
Binding assays of scu-PA, u-ATF, and UK1 was performed by real time interaction analysis using a Biacore 2000 apparatus (Biacore AB, Uppsala, Sweden). All experiments were performed at 20 o C using PBS buffer containing 0.005% (v/v) surfactant P20 (Biacore AB, running buffer). The recombinant uPAR (20 µg/ml in 10 mM sodium acetate buffer, pH 5.0) purchased from R&D system (870-UK/CF) was immobilized on a CM-5 type sensor chip using the reagents and procedures supplied with the Amine Coupling Kit (Biacore AB). The samples of scu-PA, u-ATF, and UK1 were diluted in the running buffer before injection. For general binding assay, each sample was injected over the human uPAR at a flow rate of 10 µl/min. The kinetic of binding were measured at a buffer flow of 30 µl/min, including an injection phase of 3 min followed by dissociation for 5 min. Sensor chips were regenerated at the end of each run by injection of 0.05 M acetic acid, 0.25 M NaCl. All analyses for kinetic data were performed at least in triplicate.
The sensorgrams were analyzed by non-linear curve fitting using the BIAevaluation software, version 3.0.2, assuming single-site association and dissociation models (1:1 binding with drift base line). Optimal sections of each curve was selected, and the applicability of the chosen model was ascertained by evaluating the resulting fitted curves, using the residual plot function of the software (requiring a random point scattering for the fit to be accepted) as well as calculation of χ 2 (requiring a χ 2 value below 10 in both the association and dissociation phase for acceptance). Calculated values for the association rate constant (ka) and the dissociation constant (kd) were used for deriving the equilibrium dissociation constant (Kd = kd/ka).
Endothelial cell proliferation assay BCE proliferation assay was performed as previously described (O'Reilly et al., 1994) . Cells were washed twice with PBS and trypsinized briefly with 0.05% trypsin solution. Cells were suspended in DMEM, 10% FBS, 1% antibiotics and cell number was counted using a hemocytometer. 12,500 cells/well were plated into gelatinized 24-well culture plates and were incubated (37 o C in 10 % CO2) for 24 h. The media was replaced with 0.25 ml of DMEM, 5% FBS, 1% antibiotics and the test sample applied. After 30 min of incubation, 0.25 ml of DMEM, 5% FBS, 1% antibiotics, 2 ng/ml bFGF was added to each well. After 72 h, cells were dispersed in trypsin, and counted by a trypan blue exclusion method.
Endothelial cell m igration assay
To evaluate migration, a modified Boyden chamber based assay was performed (Yamaguchi et al., 1999) . Transwell polycarbonate membrane with 8 mm pore size (Costar) was coated with 0.1% gelatin. After HUVE cells were trypsinized and suspended in M199 medium (4×10 5 cells/ml), 100 µl was added to each well in the upper chamber. The filter was placed over a bottom chamber containing 2 ng/ml VEGF165 in 0.1% BSA in M199 medium. For testing the inhibitory activity of recombinant proteins, HUVE cells were pre-incubated with the proteins in M199 medium in the cell culture incubator for 30 min before being added to the upper chamber. The assembled chamber was incubated for 5 h at 37 o C with 5% CO2 to allow cells to migrate through the gelatin-coated polycarbonate filter. The filter membrane was removed from the chamber, fixed with methanol, and stained with hematoxylin Gill No. 2 (Sigma) and eosin. Nonmigrated cells on the upper surface of the filter were removed by scraping with a cotton swab. The total number of migrated cells with nuclei per well was counted using digital photographic system.
Chorioallantoic m em brane (CAM ) assay
To determine anti-angiogenic activity in vivo, CAM assay was performed as previously described (Kim et al., 2003b) . Fertilized eggs (Pulmuone, Korea) were incubated at 37 o C, and 70% relative humidity. At day 2, a portion of albumin was removed and a window was made on day 3. At day 4.5 of incubation, test samples loaded on a thermanox cover slip (Nunc) of quarter size were applied on the CAM of individual embryos. After another 2 days' incubation, Intralipose R (KGCC, Korea) was injected into the CAM for observation of inhibition zone of angiogenesis.
R esults
Production and purification of u-ATF The recombinant plasmids constructed for the bacterial expression UK1 and u-ATF contain 6 histidine residues at carboxyl terminal end ( Figure 1A ). u-ATF was designed to span from Ser(1) to Lys(135), not including 'connecting peptide' (aa 136-158). The expressed protein exists in inclusion bodies as insoluble form. This protein was solublized, purified, and refolded in vitro, followed by final purification by size exclusion chromatography to homogeneity. The yield of purified protein is about 20% of the isolated inclusion bodies. The purified u-ATF migrated on SDS-PAGE as a single band at 18 kDa under reducing condition ( Figure 1B) . Under non-reducing condition, they migrated a little bit faster, corresponding well with the molecular weight expected. The calculated mass for u-ATF is 16,464 Da.
A nalysis of the interaction of U K 1, u-A TF, and scu-PA w ith uPAR by Biacore ATF domain of uPA has been known to act as an antagonist for uPA receptor (Lu et al., 1996; Li et al., 1998) . The interaction of these molecules with uPAR by Biacore assay was carried out in order to verify how refolded proteins, u-ATF and UK1 interact to uPAR with a measurable affinity. Recombinant human uPAR was immobilized directly to a carboxylated dextran matrix chip through amine group on uPAR, and purified UK1, u-ATF, or scu-PA was injected over the uPAR surface. Representative sensorgrams are shown Figure 2A . scu-PA and u-ATF were observed to bind to uPAR with specific affinity as expected. By contrast, UK1 did not show any binding under the identical condition over a concentration range of 15.6 nM to 500 nM, suggesting that kringle domain alone is not able to associate with uPAR (Kim et al., 2003b) ( Figure 2B ).
The kinetic parameters analyzed in another three sets of sensorgrams are summarized in Table I . u-ATF bound to uPAR with high affinity (Kd = 122±13 nM) in a dose-dependent manner. The affinity of u-ATF, which has the Kd value about 66 fold higher than that of the whole molecule, scu-PA, was mainly from the result of a decrease in ka. In the previous report, ATF exhibits about a 10-50 fold higher ED50 in SaOS-2 and U-937 cells than does DFP-uPA in the competitive binding of 125 I-ATF (Rabbani et al., 1992) . It might suggest that uPA has an additional binding site(s) or modulating domain(s) for uPA/uPAR interaction. These results also indicate u-ATF was properly refolded without significant change in binding affinity for uPAR. In case of krinlge module, bacteria-derived, refolded UK1 and yeast-derived, soluble form both also have proven to elicit almost identical anti-proliferative acivities on endothelial cells in the previous study (Kim et al., 2003a) . CD spectra measured for these two proteins also showed almost identical pattern (data not shown).
Effect of u-ATF on endothelial cell proliferation
Purified u-ATF was compared with UK1 for their inhibitory activities on BCE cell growth stimulated by bFGF (1 ng/ml). While UK1 exerted a potent growth inhibitory effect on bFGF-stimulated BCE cells in a dose-dependent manner (Figure 3 , ED50 of about 80 nM), the inhibitory potency of u-ATF was markedly lower than that of UK1, and its ED50 was beyond a concentration range measured (ED50 320 nM). u-ATF displayed a tendency of dose-dependent inhibition, compared to scu-PA which did not affect BCE cell growth at all at a concentration up to 320 nM in the previous study (Kim et al., 2003b) . 
Inhibition of VEG F-induced endothelial cell m igration by UK1 and u-ATF
The migration response of the endothelial cells is more sensitive to VEGF than bFGF (Yoshida et al., 1996) , VEGF-induced migration was employed to compare their activitities between u-ATF and UK1. VEGF (2 ng/ml) was used in the low chamber to stimulate the migration of HUVE cell subcultured to passage P3-P4. As shown in Figure 4 , purified UK1 and u-ATF also displayed dose-dependent inhibition in a concentration range of 0.01 µg/ml to 10 µg/ml, with IC50 of -1 nM, and 600 nM, respectively. UK1 was about 600 fold more potent than u-ATF. scu-PA itself did not inhibit or potentiate the VEGF-induced endothelial cell migration over a concentration range of 0.01 µg/ml to 10 µg/ml.
Anti-angiogenic activity of UK1 and u-ATF in the chick em bryo
To compare the ability of UK1 and u-ATF to inhibit in vivo angiogenesis, we used the chick chorioallantoic membrane assay. Purified UK1, and u-ATF was found to inhibit in vivo angiogenesis at the different levels ( Figure 5 ). At doses of 20 µg/embryo, UK1 showed the potent inhibitory activity (57% inhibition), whereas u-ATF showed the marginal inhibitory activity by showing 38% inhibition. Furthermore, the inhibition zone induced by high dose of u-ATF was not so distinct as that of UK1 and its dose-dependent inhibition could not be detected in this assay method.
No toxicity was observed in embryos tested.
D iscussion
Blockade of cell surface localization of uPA was reported to halt both angiogenesis and tumor growth/or metastasis (Min et al., 1996; Evans et al., 1997; Ignar et al., 1998) . Suppression of tumor growth and dissemination by adenovirus-mediated delivery of an uPA/ uPAR antagonist, the amino-terminal fragment was reported to most likely result mainly from an inhibition of angiogenesis (Li et al., 1998; Li et al., 1999; Le Gat et al., 2003) . However, the molecular basis of tumor growth and angiogenesis inhibition by uPA antagonists remains to be clarified. uPA has one kringle domain, which shares some homology with those of angiostatin kringles but distinct for being incapable of binding lysine residue. Recent our study demonstrated the kringle domain of uPA, UK1 is an anti-angiogenic molecule (Kim et al., 2003b) . In the present study, we examined anti-angiogenic acitivites of UK1 and u-ATF in the identical assay systems. Importantly, our data demonstrated the kringle domain alone is sufficient for potent anti-angiogenic activity in vitro and in vivo. However, it could not be excluded that ATF can function more effectively in tumor models, considering that ATF domain has a potential cleavage site, Lys 46 -Ser 47 for protease to produce UK1 (Bachman, 1994) and that uPA/uPAR interaction might play more important roles in tumor angiogenesis and metastasis.
Additional 45 amino acid-growth factor-like domain in u-ATF seems to divert anti-angiogenic mechanism of kringle domain. Based on the significantly different levels in inhibition of endothelial cell acitivity, u-ATF and UK1 may undergo different mechanisms for eliciting their antiangiogenic activities. In case of angiostatin, which has been studied for 10 years, its cellular and molecular action mechanism is still unclear. Our group reported that UK1 internalize specifically in endothelial cells and it also elicited a transient increase Ca 2+ flux of more than 2-fold (Kim et al., 2003b) . In inhibition of endothelial cell proliferation and migration, UK1 did not show any selectivity on angiogenic factors. The action mechanism of UK1 remains to be elucidated more precisely at the molecular level. In contrast to UK1, u-ATF binds to uPAR with high affinity, but is not able to elicit potent inhibitory activity on endothelial cell proliferation and migration. Since uPAR receptor exists in tumor cells besides endothelial cells, u-ATF seems to act in a non-selective manner, unlike UK1.
One possible explanation for the action mechanism of the differential anti-endothelial cell activities of UK1 and u-ATF can be suggested as shown in Figure 5 . The kringle domain alone acts on certain endothelial cell receptor(s) to elicit its potent anti-angiogenic activity, which might be via a mechanism similar to that for angiostatin kringles. By contrast, ATF domain mainly acts as a uPAR antagonist by binding to uPAR, although a minor portion of ATF may bind to the receptor for the kringle domain to elicit endothelial antiproliferative activity.
uPA plays important roles not only in angiogenesis, but also in tumor metastasis. A recombinant adenovirus encoding the non-catalytic ATF of mouse uPA prevents lung carcinoma metastasis (Li et al., 1998) and protects mice in a liver metastasis model of human colon carcinoma (Li et al., 1999) . In regard to metastasis, u-ATF can be more effective than UK1. However, a kringle-based inhibitor, angiostatin also suppresses tumor growth and metastasis (O'Reilly et al., 1994) . Thus, it will be interesting to examine the efficacy of UK1 and u-ATF molecules in in vivo tumor model, in regard to angiogenesis, tumor growth, and metastasis.
